NorthCore Life’s LotosPFA wins China NMPA approval for nano pulsed-field ablation system

• HongShan Capital healthcare portfolio posted multiple regulatory wins, clinical milestones, global deployments, AI recognition, and overseas surgical-network expansion in August 2026.
• Beijing CoreLife’s LotosPFA nanosecond PFA ablation system secured China NMPA clearance on July 29, positioned for local anesthesia use.
• Palm Medical began a US IDE study for its PULSE-LHD intervention, enrolling the first two patients at Henry Ford Hospital.
• Genshe Medical won NMPA clearance for its Ultra smart powered endoscopic stapler; Tugai’s 8 mm 3D/4K/fluorescence endoscope gained EU CE.
• Jinshi Biotech obtained NMPA registration for its KEYFLOW arteriovenous cannula for cardiopulmonary bypass in minimally invasive cardiac surgery.
• Aureka Biotechnologies took first place in Nature Biotechnology’s AIntibody blind test; its AuraIDE-designed antibody reached 94.7 pM KD.
• Shukun Technology launched CT whole-chest and DR whole-body imaging “agents,” targeting automated multi-condition screening with structured report output.
• Vivolight Medical deployed its P80 intravascular OCT system in Peru, completing the country’s first clinical case using multimodal intracoronary OCT.
• Edge Medical’s surgical robot supported Saudi Arabia’s first national remote robotic surgery program, integrated into a government-led virtual hospital network.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HongShan Capital (Hong Kong) Ltd. published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.